Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.
2.

A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.

Borthakur G, Dombret H, Schafhausen P, Brummendorf TH, Boissel N, Jabbour E, Mariani M, Capolongo L, Carpinelli P, Davite C, Kantarjian H, Cortes JE.

Haematologica. 2015 Jul;100(7):898-904. doi: 10.3324/haematol.2014.115279. Epub 2015 Apr 17.

3.

How we will treat chronic myeloid leukemia in 2016.

Talati C, Ontiveros EP, Griffiths EA, Wang ES, Wetzler M.

Blood Rev. 2015 Mar;29(2):137-42. doi: 10.1016/j.blre.2014.12.003. Epub 2014 Dec 17. Review.

4.

Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms.

Chen X, Shi X, Zhao C, Li X, Lan X, Liu S, Huang H, Liu N, Liao S, Zang D, Song W, Liu Q, Carter BZ, Dou QP, Wang X, Liu J.

Oncotarget. 2014 Oct 15;5(19):9118-32.

5.

Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.

Kim SH, Menon H, Jootar S, Saikia T, Kwak JY, Sohn SK, Park JS, Jeong SH, Kim HJ, Kim YK, Oh SJ, Kim H, Zang DY, Chung JS, Shin HJ, Do YR, Kim JA, Kim DY, Choi CW, Park S, Park HL, Lee GY, Cho DJ, Shin JS, Kim DW.

Haematologica. 2014 Jul;99(7):1191-6. doi: 10.3324/haematol.2013.096776. Epub 2014 Apr 4.

6.

Clinical efficacy and safety of imatinib in the management of Ph(+) chronic myeloid or acute lymphoblastic leukemia in Chinese patients.

Zhu Y, Qian SX.

Onco Targets Ther. 2014 Mar 6;7:395-404. doi: 10.2147/OTT.S38846. eCollection 2014. Review.

7.

Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.

Shi X, Chen X, Li X, Lan X, Zhao C, Liu S, Huang H, Liu N, Liao S, Song W, Zhou P, Wang S, Xu L, Wang X, Dou QP, Liu J.

Clin Cancer Res. 2014 Jan 1;20(1):151-63. doi: 10.1158/1078-0432.CCR-13-1063. Epub 2013 Dec 12.

8.

Rapid Evolution to Blast Crisis Associated with a Q252H ABL1 Kinase Domain Mutation in e19a2 BCR-ABL1 Chronic Myeloid Leukaemia.

McCarron SL, Maher K, Kelly J, Ryan MF, Langabeer SE.

Case Rep Hematol. 2013;2013:490740. doi: 10.1155/2013/490740. Epub 2013 Sep 16.

9.

Management of imatinib-resistant patients with chronic myeloid leukemia.

Bhamidipati PK, Kantarjian H, Cortes J, Cornelison AM, Jabbour E.

Ther Adv Hematol. 2013 Apr;4(2):103-17. doi: 10.1177/2040620712468289.

10.

The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure.

Jabbour E, Kantarjian H, Ghanem H, O'Brien S, Quintas-Cardama A, Garcia-Manero G, Cardenas M, Cortes J.

Clin Lymphoma Myeloma Leuk. 2013 Jun;13(3):302-6. doi: 10.1016/j.clml.2012.12.005. Epub 2013 Jan 12.

11.

Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance.

Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Hughes TP, Saglio G, Radich JP, Kim DW, Martinelli G, Reynolds J, Woodman RC, Baccarani M, Kantarjian HM.

Leukemia. 2013 Apr;27(4):907-13. doi: 10.1038/leu.2012.305. Epub 2012 Nov 6.

12.

Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure.

Cornelison AM, Kantarjian H, Cortes J, Jabbour E.

Clin Lymphoma Myeloma Leuk. 2011 Jun;11 Suppl 1:S101-10. doi: 10.1016/j.clml.2011.02.009. Epub 2011 Apr 28.

13.

The treatment of pediatric chronic myelogenous leukemia in the imatinib era.

Lee JW, Chung NG.

Korean J Pediatr. 2011 Mar;54(3):111-6. doi: 10.3345/kjp.2011.54.3.111. Epub 2011 Mar 31.

14.

Tyrosine kinase inhibitors: Multi-targeted or single-targeted?

Broekman F, Giovannetti E, Peters GJ.

World J Clin Oncol. 2011 Feb 10;2(2):80-93. doi: 10.5306/wjco.v2.i2.80.

15.

Patan hospital experience in treating philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec (imatinib mesylate); the first generation specific tyrosine kinase inhibitor.

Kayastha GK, Gurung P, Acharya PK, Paudyal BP, Hayes B, Zimmerman M, Karki A, Mansfield AS.

BMC Blood Disord. 2010 Dec 7;10:8. doi: 10.1186/1471-2326-10-8.

16.

Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.

Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero G, Wierda W, Ravandi F, Borthakur G, Rios MB, Cortes J.

Blood. 2011 Feb 10;117(6):1822-7. doi: 10.1182/blood-2010-07-293977. Epub 2010 Oct 28.

17.

Hematopoietic stem cell transplantation for leukemia.

Wayne AS, Baird K, Egeler RM.

Pediatr Clin North Am. 2010 Feb;57(1):1-25. doi: 10.1016/j.pcl.2009.11.005. Review.

18.

Development and targeted use of nilotinib in chronic myeloid leukemia.

Fava C, Kantarjian H, Cortes J, Jabbour E.

Drug Des Devel Ther. 2009 Feb 6;2:233-43.

19.

Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer.

Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M, Cascone T, Mills GB, Heymach JV, Johnson FM.

Clin Cancer Res. 2009 Nov 15;15(22):6852-61. doi: 10.1158/1078-0432.CCR-09-0767. Epub 2009 Oct 27.

20.

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance.

Martinelli G, Iacobucci I, Soverini S, Palandri F, Castagnetti F, Rosti G, Baccarani M.

Biologics. 2007 Jun;1(2):121-7.

Items per page

Supplemental Content

Write to the Help Desk